The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.

Auteurs

Debien V, Agostinetto E, Bruzzone M, Ceppi M, Martins-Branco D, Molinelli C, Jacobs F, Nader-Marta G, Lambertini M, de Azambuja E

  • Date de publication

    February 2024

  • Type

    Article

  • Review

    Clin Breast Cancer

  • Researcher's name

    NADER MARTA GUILHERME

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    38514306

  • DOI

    10.1016/j.clbc.2024.02.012